drug development

It’s becoming clear that longevity as a theme has resonated with investors, though it appears it will be some time before more generalist investors take interest.

In the creation of a new drug, there comes a point where you have to finally put the molecule in a real creature — one at a time — and see if it actually does what you think it does. Manifold Bio&

We believe in a future where psychedelic therapy will be as common as going to the dentist, but the path won’t be easy.

Adam Goulburn, a partner at Lux Capital, was first struck by Eikon Therapeutics’ pitch to use super microscopes to develop drugs when founder Eric Betzig posed a simple question: How can you underst

Before the pandemic forced remote work, school and research to the forefront, decentralized clinical trials were probably on the horizon. Now, they’re here in earnest.  This week, precision psychia

Vinehealth, a 2018-founded, London-based digital health startup that’s built an app offering personalized support for cancer patients while also making it easier to gather patient-reported outco

The drug development space is continuing to attract more and more investment. On Thursday, another major player, Generate Biomedicines, announced a $370 million Series B round.  Generate Biomedicines

The necessity of animal testing is a sad one for the process of drug discovery, but there’s seemingly no good alternative to mice, even though they’re not particularly accurate human analo

The Department of Health and Human Services (HHS) Office of the Inspector General will review the FDA’s accelerated approval pathway, the office announced Wednesday. This sweeping review comes just

Absci Corp., a Vancouver company behind a multifaceted drug development platform, went public on Thursday. It’s another sign of snowballing interest in new approaches to drug development — a t

On Monday, a 17-year drought in the world of Alzheimer’s drugs ended with the FDA approval of Biogen’s Aduhlem (aducanumab). The controversy behind the FDA’s decision was considerable, but it do

Sensor data from smartphones and wearables can meaningfully predict an individual’s ‘biological age’ and resilience to stress, according to Gero AI. The ‘longevity’ start

If you or a loved one has ever undergone a tumor removal as part of cancer treatment, you’re likely familiar with the period of uncertainty and fear that follows. Will the cancer return, and if so,

Resilience, a new biopharmaceutical company backed by $800 million in financing from investors including ARCH Venture Partners and 8VC, has emerged from stealth to transform the way that drugs and the

The clinical trial management software developer Medable has raised $91 million in a new round of financing as life sciences companies struggle with how to conduct the necessary validation studies of

Within3, a collaboration and communication service for the biotech and pharma industries, has raised over $100 million in new financing, the company said. The investment came from Insight Partners wit

With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning pl

Bit Bio, the new startup that pitches itself as the “enter button for the keyboard to the software of life,” only needed three weeks to raise its latest $41.5 million round of funding. Ori

Today and going forward, billions of tiny devices will act as an extension of our brains, feelings and emotions as a natural extension of everyday life.

Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuti